CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors, PD-1/PD-L1 inhibitors, have been applied to the treatment of a variety of malignant tumors including non-small-cell lung cancer (NSCLC) [1–3], melanoma [4–6], head and neck squamous cell carcinoma (HNSCC) [7, 8], and metastatic renal cell cancer [9] and have become the standard treatment for some cancers, which are pretty promising.